###begin article-title 0
###xml 72 77 <span type="species:ncbi:10090">Mouse</span>
Dopamine-Independent Locomotor Actions of Amphetamines in a Novel Acute Mouse Model of Parkinson Disease
###end article-title 0
###begin article-title 1
###xml 2 7 <span type="species:ncbi:10090">Mouse</span>
A Mouse Model for Parkinson's Disease
###end article-title 1
###begin p 2
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 458 462 <span type="species:ncbi:10090">mice</span>
Brain dopamine is critically involved in movement control, and its deficiency is the primary cause of motor symptoms in Parkinson disease. Here we report development of an animal model of acute severe dopamine deficiency by using mice lacking the dopamine transporter. In the absence of transporter-mediated recycling mechanisms, dopamine levels become entirely dependent on de novo synthesis. Acute pharmacological inhibition of dopamine synthesis in these mice induces transient elimination of striatal dopamine accompanied by the development of a striking behavioral phenotype manifested as severe akinesia, rigidity, tremor, and ptosis. This phenotype can be reversed by administration of the dopamine precursor, L-DOPA, or by nonselective dopamine agonists. Surprisingly, several amphetamine derivatives were also effective in reversing these behavioral abnormalities in a dopamine-independent manner. Identification of dopamine transporter- and dopamine-independent locomotor actions of amphetamines suggests a novel paradigm in the search for prospective anti-Parkinsonian drugs.
###end p 2
###begin p 3
Identification of dopamine transporter- and dopamine- independent locomotor actions of amphetamines suggests a novel paradigm in the search for prospective anti-Parkinsonian drugs.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 156 157 156 157 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b01">1</xref>
###xml 158 159 158 159 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b03">3</xref>
###xml 712 713 712 713 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b04">4</xref>
###xml 714 715 714 715 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b06">6</xref>
###xml 858 859 858 859 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">L</italic>
###xml 904 905 904 905 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b01">1</xref>
###xml 906 907 906 907 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b03">3</xref>
###xml 1015 1016 1015 1016 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b07">7</xref>
###xml 1017 1018 1017 1018 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b08">8</xref>
###xml 1167 1168 1167 1168 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b09">9</xref>
###xml 1465 1466 1465 1466 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1469 1470 1469 1470 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1525 1527 1525 1527 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b10">10</xref>
###xml 1528 1530 1528 1530 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b11">11</xref>
###xml 1668 1670 1668 1670 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b12">12</xref>
###xml 1671 1673 1671 1673 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b13">13</xref>
The phenylethylamine derivative dopamine (DA) is critically involved in a wide variety of vital functions such as locomotion, feeding, emotion, and reward [1-3]. Major DA systems in the brain originate from brainstem DA neurons located in the substantia nigra pars compacta (SNc) and the ventral tegmental area (VTA). SNc neurons project mainly to the caudate/putamen or dorsal striatum (nigrostriatal system), whereas VTA neurons send their axons to the ventral striatum including the nucleus accumbens, as well as certain other limbic (mesolimbic system) and cortical areas (mesocortical system). Small DA-containing cell groups located primarily in the hypothalamus comprise the tuberoinfundibular DA system [4-6]. DA is synthesized from tyrosine by the rate-limiting enzyme tyrosine hydroxylase (TH), to produce L-DOPA which is quickly decarboxylated by L-aromatic acid decarboxylase (L-AADC) to DA [1,3]. Intraneuronal DA is accumulated into synaptic vesicles by the vesicular monoamine transporter-2 (VMAT2) [7,8]. DA released into the extracellular space exerts its physiological functions via activation of G protein-coupled D1-like and D2-like DA receptors [9]. Finally, DA in the extracellular space is subject to dilution by diffusion and metabolic degradation; however the major route of DA clearance from the extracellular space in the striatum/nucleus accumbens is the rapid recycling of the neurotransmitter back into dopaminergic terminals by the Na+/Cl--dependent plasma membrane dopamine transporter (DAT) [10,11]. Recycled DA in the dopaminergic terminals is then stored in the large intracellullar storage pool available for subsequent re-release [12,13] .
###end p 5
###begin p 6
###xml 408 410 408 410 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b14">14</xref>
###xml 411 413 411 413 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b17">17</xref>
###xml 770 772 770 772 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b18">18</xref>
###xml 817 819 817 819 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b19">19</xref>
###xml 820 822 820 822 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b20">20</xref>
###xml 894 896 894 896 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b21">21</xref>
###xml 1049 1051 1049 1051 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b22">22</xref>
###xml 1052 1054 1052 1054 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b23">23</xref>
###xml 1589 1591 1589 1591 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b21">21</xref>
###xml 1592 1594 1592 1594 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b24">24</xref>
###xml 1595 1597 1595 1597 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b25">25</xref>
###xml 1952 1954 1952 1954 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b16">16</xref>
###xml 1955 1957 1955 1957 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b26">26</xref>
###xml 1958 1960 1958 1960 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b28">28</xref>
###xml 1452 1460 <span type="species:ncbi:9606">patients</span>
It is well established that DA neurotransmission in both dorsal and ventral striatum is essential for normal locomotor functions, and progressive degeneration of DA neurons in these areas is a known cause of Parkinson disease (PD). In most cases, PD becomes clinically apparent when the loss of dopaminergic neurons reaches 60%-70%, which leads to functional dysregulation of the related neuronal circuitry [14-17]. Major motor manifestations of DA deficiency in PD include, but are not limited to, resting tremor (tremor occurring in the absence of voluntary movement), rigidity (tonically increased muscle tone), bradykinesia/akinesia (slowness/difficulty in initiating movement), gait disturbance and postural instability, facial masking, and decreased eye-blinking [18]. Presently, there is no known cure for PD [19,20], however its symptoms can be controlled by therapeutic interventions [21]. DA replacement therapy by administration of the DA precursor, L-DOPA, has been used for many years and remains the gold standard for treatment of PD [22,23]. However, the efficacy of this treatment wanes with time, and fluctuations in motor performance as well as psychotic reactions and dyskinesias often develop. DA agonists, as well as several other classes of drugs directly or indirectly affecting DA function (monoamine oxidase [MAO] inhibitors, COMT [catechol-o-methyl transferase] inhibitors, and amantadine), have some beneficial effects in PD patients, but they are mostly used either at early stages of PD or are applied as adjunct medications to enhance the benefits of L-DOPA [21,24,25]. Due to these limitations of existing therapeutic approaches, the development of better anti-Parkinsonian drugs remains a major objective of PD research. Several lines of evidence suggest that development of novel non-dopaminergic approaches aimed at bypassing impaired dopaminergic transmission would be beneficial in PD, particularly at later stages [16,26-28], however it is still unclear if these treatments would just potentiate action of residual DA or act completely independently of DA.
###end p 6
###begin p 7
###xml 230 232 230 232 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b29">29</xref>
###xml 233 235 233 235 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b36">36</xref>
###xml 316 317 316 317 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b03">3</xref>
###xml 318 319 318 319 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b07">7</xref>
###xml 320 321 320 321 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b08">8</xref>
###xml 489 491 489 491 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b11">11</xref>
###xml 564 566 564 566 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b12">12</xref>
###xml 567 569 567 569 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b13">13</xref>
###xml 570 572 570 572 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b37">37</xref>
###xml 947 949 947 949 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b12">12</xref>
###xml 950 952 950 952 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b13">13</xref>
###xml 444 448 <span type="species:ncbi:10090">mice</span>
###xml 482 486 <span type="species:ncbi:10090">mice</span>
###xml 626 630 <span type="species:ncbi:10090">mice</span>
###xml 752 756 <span type="species:ncbi:10090">mice</span>
###xml 886 890 <span type="species:ncbi:10090">mice</span>
A number of animal models of DA deficiency, based on pharmacologic, neurotoxic, or genetic approaches, have been developed to understand basic pathological processes leading to PD and/or to search for novel principles of therapy [29-36]. However, in rodents, the prolonged absence of DA is not compatible with life [3,7,8], and animals with chronic severe DA depletion are generally not available for routine experimentation. We have developed mice lacking a functional DAT (DAT-KO mice) [11] that display remarkable alterations in the compartmentalization of DA [12,13,37]. Lack of the DAT-mediated inward transport in these mice results in an elevated extracellular DA and at least 95% decreased intracellular DA stores. Unlike normal animals, these mice demonstrate remarkable dependence of the remaining DA on ongoing synthesis, and pharmacologic blockade of DA synthesis in DAT-KO mice provides an effective approach to eliminate DA acutely [12,13].
###end p 7
###begin p 8
###xml 524 526 521 523 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b10">10</xref>
###xml 527 529 524 526 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b38">38</xref>
###xml 530 532 527 529 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b39">39</xref>
###xml 682 684 679 681 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b38">38</xref>
###xml 685 687 682 684 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b40">40</xref>
###xml 688 690 685 687 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b41">41</xref>
###xml 1042 1044 1036 1038 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b42">42</xref>
###xml 1094 1096 1088 1090 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b43">43</xref>
###xml 1097 1099 1091 1093 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b44">44</xref>
Substituted phenylethylamine derivatives, amphetamines, that are structurally similar to DA and the endogenous trace amine beta-phenylethylamine, represent a well-known group of compounds that potently affect psychomotor functions. Amphetamines are known to interact with plasma membrane monoamine transporters, including DAT, norepinephrine (NE) transporter (NET), and serotonin transporter. This complex interaction results in transporter-dependent efflux of monoamines into extracellular space from intraneuronal stores [10,38,39]. It is commonly believed that DAT-mediated efflux of DA is primarily responsible for the psychostimulant and hyperlocomotor actions of these drugs [38,40,41]. Intriguingly, recent studies have identified novel transporter-independent targets of amphetamines. It has been shown that amphetamines, as well as beta-phenylethylamine, some monoamine metabolites, and several drugs affecting monoaminergic transmission, can directly activate specific G protein-coupled trace amine (trace amine 1 [TA1]) receptors [42] with currently unknown functional consequences [43,44].
###end p 8
###begin p 9
###xml 168 172 <span type="species:ncbi:10090">mice</span>
###xml 279 283 <span type="species:ncbi:10090">mice</span>
###xml 289 293 <span type="species:ncbi:10090">mice</span>
We report here that the pharmacologic inhibition of the rate-limiting enzyme of DA synthesis, TH, almost immediately depletes brain DA to undetectable levels in DAT-KO mice and induces a transient recapitulation of essentially all PD symptoms for up to 16 h. DA-deficient DAT-KO mice (DDD mice) thus represent an acute PD model that is useful for studying the efficacy of compounds that potentially can restore control of locomotion in the absence of any contribution of the dopaminergic system. By using this approach, we found that several amphetamine derivatives can counteract the behavioral manifestations of severe DA deficiency, suggesting that, in addition to well-known DA-mediated effects, amphetamine-like compounds can also affect motor functions in a DA- and DAT-independent manner.
###end p 9
###begin title 10
Results
###end title 10
###begin title 11
###xml 73 77 <span type="species:ncbi:10090">Mice</span>
A Pharmacologic Approach for Provoking Selective DA Deficiency in DAT-KO Mice
###end title 11
###begin p 12
###xml 28 29 24 25 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 89 91 81 83 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b29">29</xref>
###xml 92 94 84 86 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b45">45</xref>
###xml 95 97 87 89 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b46">46</xref>
###xml 447 449 435 437 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b29">29</xref>
###xml 450 452 438 440 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b45">45</xref>
###xml 453 455 441 443 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b46">46</xref>
###xml 774 776 762 764 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b29">29</xref>
###xml 777 779 765 767 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b45">45</xref>
###xml 780 782 768 770 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b46">46</xref>
###xml 978 980 966 968 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b33">33</xref>
###xml 981 983 969 971 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b47">47</xref>
###xml 984 986 972 974 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b49">49</xref>
###xml 1133 1135 1121 1123 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b33">33</xref>
###xml 1136 1138 1124 1126 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b47">47</xref>
###xml 1139 1141 1127 1129 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b50">50</xref>
###xml 208 213 <span type="species:ncbi:10090">mouse</span>
###xml 1027 1031 <span type="species:ncbi:10090">mice</span>
The ability of alpha-methyl-p-tyrosine (alphaMT), a potent irreversible inhibitor of TH [29,45,46], to impede production of brain DA suggests a simple, but straightforward, strategy for producing an acute PD mouse model. However, numerous studies have documented that treatment of normal animals with alphaMT results only in a relatively slow and partial depletion of DA in brain tissues that is not sufficient for generation of PD-like symptoms [29,45,46]. This limited depletion is based upon how DA is stored. It is believed that the large intraneuronal DA storage pool that normally exists in striatal DA terminals provides sufficient DA to release and recycle back into releasing terminals up to the time when newly synthesized TH starts to regain its functional role [29,45,46]. Thus, in a normal animal, complete depletion of striatal DA is unachievable by TH inhibition alone, and additional depletion of vesicular DA by VMAT2 inhibitors, such as reserpine is required [33,47-49]. Protocols designed for wild-type [WT] mice that use a dual inhibitor strategy (VMAT2 plus TH inhibitors) deplete DA to 1%-2% of control levels [33,47-50], but the levels of other monoamine neurotransmitters that are substrates for VMAT2 are also severely affected. This nonselective targeting of monoaminergic signaling generally results in very complicated phenotypes that are not necessarily reflective of classic PD.
###end p 12
###begin p 13
###xml 172 174 172 174 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b12">12</xref>
###xml 311 313 311 313 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b51">51</xref>
###xml 341 343 341 343 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b52">52</xref>
###xml 501 503 501 503 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b13">13</xref>
###xml 816 818 812 814 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b12">12</xref>
###xml 819 821 815 817 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b13">13</xref>
###xml 822 824 818 820 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b37">37</xref>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
###xml 244 248 <span type="species:ncbi:10090">mice</span>
###xml 293 297 <span type="species:ncbi:10090">mice</span>
###xml 572 576 <span type="species:ncbi:10090">mice</span>
###xml 723 727 <span type="species:ncbi:10090">mice</span>
In the absence of any pharmacologic treatment, the intraneuronal vesicular stores of DA in the striatum of DAT-KO mice are already profoundly depleted by at least 20-fold [12]. This selective depletion of DA in dopaminergic terminals of DAT-KO mice, as well as analogous depletion observed in mice lacking NET [51] or serotonin transporter [52] with NE and serotonin (5-HT), respectively, reflects the critical role of transporter-mediated recycling in the maintenance of intracellular storage pools [13]. With loss of the major intracellular storage pool of DA in DAT-KO mice, both the intracellular and extracellular levels of DA in the striatum become critically dependent upon ongoing DA synthesis. Therefore in DAT-KO mice, acute TH inhibition alone by alphaMT is sufficient to induce profound depletion of DA [12,13,37].
###end p 13
###begin p 14
###xml 158 166 154 162 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g001">Figure 1</xref>
###xml 205 207 201 203 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b13">13</xref>
###xml 333 341 329 337 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g001">Figure 1</xref>
###xml 715 723 707 715 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g001">Figure 1</xref>
###xml 879 881 871 873 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b29">29</xref>
###xml 882 884 874 876 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b45">45</xref>
###xml 119 123 <span type="species:ncbi:10090">mice</span>
###xml 252 256 <span type="species:ncbi:10090">mice</span>
###xml 409 413 <span type="species:ncbi:10090">mice</span>
###xml 501 505 <span type="species:ncbi:10090">mice</span>
###xml 610 614 <span type="species:ncbi:10090">mice</span>
###xml 767 771 <span type="species:ncbi:10090">mice</span>
###xml 983 987 <span type="species:ncbi:10090">mice</span>
To explore this phenomenon in detail, we first measured the time-course of striatal DA depletion in DAT-KO and control mice following treatment with alphaMT (Figure 1). In agreement with previous studies [13], we observed that in saline-treated DAT-KO mice, striatal tissue levels of DA were about 20-fold lower than in WT controls (Figure 1A). The systemic administration of alphaMT (250 mg/kg IP) to DAT-KO mice produced rapid (15 min) and virtually complete (down to 5% of control levels in DAT-KO mice that is equivalent to less than 0.2% of WT control levels) depletion of striatal DA. In contrast, in WT mice the same treatment resulted in a relatively slow (4 h) depletion of only 60% of striatal tissue DA (Figure 1B). The duration of the depletion in DAT-KO mice was extensive, lasting up to 16 h, until a recovery of DA, related to the de novo synthesis of TH, occurs [29,45]. Notably, the rate of recovery of striatal DA levels was approximately the same in WT and DAT-KO mice.
###end p 14
###begin p 15
###xml 646 654 646 654 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g001">Figure 1</xref>
###xml 902 910 898 906 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g001">Figure 1</xref>
###xml 269 273 <span type="species:ncbi:10090">mice</span>
###xml 338 342 <span type="species:ncbi:10090">mice</span>
###xml 606 610 <span type="species:ncbi:10090">mice</span>
###xml 640 644 <span type="species:ncbi:10090">mice</span>
###xml 750 754 <span type="species:ncbi:10090">mice</span>
###xml 896 900 <span type="species:ncbi:10090">mice</span>
###xml 944 948 <span type="species:ncbi:10090">mice</span>
Because DA itself serves as a precursor for neuronal production of NE in NE neurons, the inhibition of TH should also impact NE production. To test the impact of TH inhibition on the NE system, the frontal cortex tissue NE concentrations were measured in WT and DAT-KO mice. As opposed to the DAT, NET expression is not altered in DAT-KO mice so that the storage pool, which is by far the predominant reservoir of NE in NE-enriched regions such as the frontal cortex, should not be significantly altered in these mutants. Accordingly, the levels of NE in the frontal cortex tissue of saline-treated DAT-KO mice did not vary from that of WT mice (Figure 1C). Furthermore, alphaMT (250 mg/kg IP) treatment induced similar NE depletion in WT and DAT-KO mice by about 60% in 8 h after treatment. Importantly, the rates of partial NE depletion and recovery were almost identical between WT and DAT-KO mice (Figure 1D). Thus, TH inhibition in DAT-KO mice induces rapid severe depletion of DA, but only partially and slowly affects NE, indicating selectivity of this marked depletion to neurons expressing the DAT.
###end p 15
###begin p 16
###xml 341 349 333 341 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g001">Figure 1</xref>
###xml 411 419 403 411 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g001">Figure 1</xref>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 335 339 <span type="species:ncbi:10090">mice</span>
###xml 404 408 <span type="species:ncbi:10090">mice</span>
###xml 502 506 <span type="species:ncbi:10090">mice</span>
In order to demonstrate that targeting of TH by alphaMT depletes the functional extracellular pool of DA in living animals, we measured extracellular levels of striatal DA in freely moving mice by in vivo microdialysis. In agreement with total tissue DA data, alphaMT treatment essentially eliminated extracellular DA levels in DAT-KO mice (Figure 1F), whereas only a partial decrease was observed in WT mice. (Figure 1E). Thus, both intracellular and extracellular DA levels in the striatum of DAT-KO mice are critically dependent upon ongoing synthesis.
###end p 16
###begin title 17
###xml 23 27 <span type="species:ncbi:10090">Mice</span>
DA Depletion in DAT-KO Mice Results in a Loss of Motor Control
###end title 17
###begin p 18
###xml 205 213 201 209 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g002">Figure 2</xref>
###xml 219 227 215 223 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="sv001">Video S1</xref>
###xml 545 553 537 545 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g003">Figure 3</xref>
###xml 623 631 615 623 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g003">Figure 3</xref>
###xml 637 638 629 630 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g003">3</xref>
###xml 668 676 660 668 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g003">Figure 3</xref>
###xml 719 727 711 719 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g003">Figure 3</xref>
###xml 750 758 742 750 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g003">Figure 3</xref>
###xml 784 792 776 784 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g003">Figure 3</xref>
###xml 812 820 804 812 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g003">Figure 3</xref>
###xml 835 843 827 835 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g003">Figure 3</xref>
###xml 855 863 847 855 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g002">Figure 2</xref>
###xml 892 893 884 885 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b03">3</xref>
###xml 894 896 886 888 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b53">53</xref>
###xml 897 899 889 891 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b58">58</xref>
###xml 1090 1098 1078 1086 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g001">Figure 1</xref>
###xml 1451 1459 1435 1443 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g003">Figure 3</xref>
###xml 1557 1559 1541 1543 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b59">59</xref>
###xml 1648 1656 1632 1640 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g003">Figure 3</xref>
###xml 2196 2204 2180 2188 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="sv001">Video S1</xref>
###xml 2343 2351 2327 2335 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g001">Figure 1</xref>
###xml 2468 2476 2452 2460 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g003">Figure 3</xref>
###xml 2695 2697 2671 2673 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b60">60</xref>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
###xml 253 257 <span type="species:ncbi:10090">mice</span>
###xml 263 267 <span type="species:ncbi:10090">mice</span>
###xml 406 410 <span type="species:ncbi:10090">mice</span>
###xml 426 430 <span type="species:ncbi:10090">mice</span>
###xml 949 953 <span type="species:ncbi:10090">mice</span>
###xml 1034 1038 <span type="species:ncbi:10090">mice</span>
###xml 1127 1131 <span type="species:ncbi:10090">mice</span>
###xml 1254 1258 <span type="species:ncbi:10090">mice</span>
###xml 1602 1606 <span type="species:ncbi:10090">mice</span>
###xml 2072 2076 <span type="species:ncbi:10090">mice</span>
###xml 2413 2417 <span type="species:ncbi:10090">mice</span>
###xml 2570 2574 <span type="species:ncbi:10090">mice</span>
It is well known that DA plays a pivotal role in the control of various aspects of locomotor behaviors. Severe depletion of DA in alphaMT-treated DAT-KO mice results in a very specific akinetic phenotype (Figure 2; see Video S1). The DA-depleted DAT-KO mice (DDD mice) become akinetic almost immediately after treatment, in contrast to the essentially normal motor function displayed by alphaMT-treated WT mice. Moreover, DDD mice develop extreme rigidity, body tremor, and ptosis (droopy eyelids). These behaviors are evident on several tests (Figure 3). Akinesia was assessed by evaluating horizontal locomotor activity (Figure 3A and 3B) and by an "akinesia" test (Figure 3C); rigidity assessed by a catalepsy test (Figure 3D), a "grasping" test (Figure 3E), and a "bracing" test (Figure 3F); whereas tremor (Figure 3G) and ptosis (Figure 3H, see also Figure 2B) were visually determined [3,53-58]. These behaviors were analyzed in WT and DAT-KO mice for 4 h after a alphaMT treatment when depletion of DA is most severe in DAT-KO mice but with relatively minor effect on NE levels (see Figure 1). In all these measures DDD mice differed significantly from their WT littermates or saline-treated controls. Importantly, these abnormal behaviors in DDD mice, with the exception of ptosis, became maximal during the 30- to 60-min period following alphaMT exposure, thus correlating with the rate of DA depletion. Ptosis developed substantially later (Figure 3H), suggesting an additional contribution of NE depletion to the full magnitude of this response [59]. Importantly, the righting reflex of DDD mice was normal at all time periods analyzed (Figure 3I), indicating that this akinesia is not related to global sedation but rather to deficient movement control. It should be noted also that this global phenotype, which might be viewed as "freezing," can be on some occasions temporarily disrupted by an acoustic startle or other stressful stimulus. However, after manifesting a few movements, the animals return to an akinetic state (data not shown). Strikingly, DDD mice, when placed in water, were able to swim with periods of floating and active swimming for at least a 3-min period (see Video S1), indicating that under certain conditions, movement can occur essentially without DA. Finally, in agreement with neurochemical data (see Figure 1B), the recovery from this profound akinetic phenotype in DDD mice occurs approximately 16-24 h following treatment (Figure 3J). The full recovery of animals allows repeated treatment with alphaMT, and, in fact, DAT-KO mice chronically treated with alphaMT (100 mg/kg, IP, once every 3 d) for a period of 40 wk showed no negative consequences [60].
###end p 18
###begin title 19
###xml 66 70 <span type="species:ncbi:10090">Mice</span>
L-DOPA and Nonselective DA Agonists Restore Motor Activity in DDD Mice
###end title 19
###begin p 20
###xml 163 164 163 164 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b03">3</xref>
###xml 165 167 165 167 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b15">15</xref>
###xml 168 170 168 170 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b45">45</xref>
###xml 171 173 171 173 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b61">61</xref>
###xml 217 225 217 225 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g004">Figure 4</xref>
###xml 282 290 282 290 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g004">Figure 4</xref>
###xml 292 293 292 293 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g004">4</xref>
###xml 505 513 505 513 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g004">Figure 4</xref>
###xml 515 516 515 516 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g004">4</xref>
###xml 620 622 620 622 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b11">11</xref>
###xml 623 625 623 625 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b13">13</xref>
###xml 695 703 695 703 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g003">Figure 3</xref>
###xml 393 397 <span type="species:ncbi:10090">mice</span>
###xml 499 503 <span type="species:ncbi:10090">mice</span>
###xml 577 581 <span type="species:ncbi:10090">mice</span>
The locomotor restoring effects exhibited by L-DOPA and DA agonists in various models of DA deficiency form one of the best-established paradigms in neuroscience [3,15,45,61]. As expected, high doses of L-DOPA alone (Figure 4A), or lower doses of L-DOPA given along with carbidopa (Figure 4B-4D) to reduce its peripheral metabolism via L-AADC inhibition, effectively restore locomotion in DDD mice. In fact, these treatments temporarily restore locomotion to the levels observed in untreated DAT-KO mice (Figure 4A-4D), which are normally at least 10 times more active than WT mice when placed into a novel environment [11,13]. Other manifestations associated with DA deficiency as described in Figure 3 were also essentially completely reversed (data not shown).
###end p 20
###begin p 21
###xml 207 215 207 215 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g004">Figure 4</xref>
###xml 221 222 221 222 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g004">4</xref>
###xml 539 547 539 547 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g004">Figure 4</xref>
###xml 549 550 549 550 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g004">4</xref>
###xml 696 704 696 704 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g004">Figure 4</xref>
###xml 818 820 818 820 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b62">62</xref>
###xml 253 257 <span type="species:ncbi:10090">mice</span>
Efficacy of exogenous direct DA agonists was also tested in this model. Although the nonselective D1/D2 DA receptor agonists apomorphine and pergolide were somewhat effective in inducing forward locomotion (Figure 4E and 4F), the activity levels of DDD mice following these treatments were substantially lower than those induced by L-DOPA. Strikingly, the selective D1 DA receptor agonist (+)-SKF81297 and D2 DA receptor agonists, bromocriptine and quinpirole, were ineffective in inducing forward locomotion when administered separately (Figure 4G-4I). However, the combined administration of the D1 and D2 agonists (+)-SKF81297 plus quinpirole restored movement and induced forward locomotion (Figure 4J), supporting the well-established cooperative interaction of D1 and D2-like DA receptors in locomotor activity [62].
###end p 21
###begin title 22
###xml 61 65 <span type="species:ncbi:10090">Mice</span>
Movement-Restoring Actions of Amphetamine Derivatives in DDD Mice
###end title 22
###begin p 23
###xml 437 444 437 444 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pbio-0030271-t001">Table 1</xref>
###xml 622 624 622 624 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b21">21</xref>
###xml 625 627 625 627 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b26">26</xref>
###xml 628 630 628 630 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b27">27</xref>
###xml 631 633 631 633 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b48">48</xref>
###xml 634 636 634 636 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b49">49</xref>
###xml 1415 1422 1415 1422 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pbio-0030271-t001">Table 1</xref>
###xml 1454 1455 1454 1455 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">L</italic>
###xml 1749 1750 1747 1748 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1815 1816 1813 1814 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2016 2017 2008 2009 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2036 2037 2028 2029 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 2113 2115 2105 2107 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b59">59</xref>
###xml 2182 2184 2171 2173 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b44">44</xref>
###xml 2185 2187 2174 2176 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b63">63</xref>
###xml 427 431 <span type="species:ncbi:10090">mice</span>
###xml 612 620 <span type="species:ncbi:9606">patients</span>
###xml 655 659 <span type="species:ncbi:10090">mice</span>
###xml 876 880 <span type="species:ncbi:10090">mice</span>
###xml 943 947 <span type="species:ncbi:10090">mice</span>
###xml 1566 1570 <span type="species:ncbi:10090">mice</span>
###xml 1940 1944 <span type="species:ncbi:10090">mice</span>
###xml 2461 2465 <span type="species:ncbi:10090">mice</span>
The loss of DA signaling that creates the motor symptoms of PD occurs upstream of many nondopaminergic pathways. This suggests that activation or inhibition of some of these downstream neuronal circuits could potentially reverse the motor deficits independent of restoration of DA activity. We, therefore, tested several non-dopaminergic compounds that potentially could reverse the consequences of severe DA deficiency in DDD mice (see Table 1). Many of these compounds have been found to be effective in restoring some aspects of movement control in one or another experimental animal model of PD and/or in PD patients [21,26,27,48,49]. However, in DDD mice none of the drugs were effective in restoring the major aspects of movement control required for forward locomotion (distance traveled). Although it is likely that the lack of locomotor effects of these drugs in DDD mice is related to an unprecedented level of DA depletion in these mice, it should be emphasized that in our studies only a few doses or combinations of drugs were tested. Furthermore, several treatments, although not inducing forward locomotion per se, were, nevertheless, somewhat effective in reversing other manifestations of DA deficiency. For example, the NMDA receptor antagonist MK-801 was able to reduce rigidity and promote weak, disorganized movement that however did not result in a significant increase in forward locomotion (Table 1). Synthetic amino acid L-DOPS (L-threo-3,4-dihydroxyphenylserine), which is decarboxylated to NE by L-AADC, selectively reversed ptosis in DDD mice. Cumulative dosing experiments revealed ptosis scores (measured 1h after each treatment) of 2.50 +/- 0.28 after 100 mg/kg, 0 after 200 mg/kg, and 0 after 400 mg/kg IP of L-DOPS (n = 4), whereas corresponding values for saline-treated controls (n = 6) were 3.3 +/- 0.3, 3.7 +/- 0.2, and 3.7 +/- 0.2, respectively. Effects of 200 and 400 mg/kg of L-DOPS on ptosis in DDD mice were significantly different as compared to respective control values (p < 0.05, Student's t-test) supporting an important role of NE in this behavioral manifestation [59]. Similarly, high doses of the trace amine beta-phenylethylamine [44,63] (with or without concomitant inhibition of MAO) did not induce forward locomotion, but did promote weak stereotypic reactions, such as head-weaving and sniffing (data not shown). Further investigations will be required to fully evaluate the efficacy of these drugs in DDD mice.
###end p 23
###begin p 24
###xml 145 146 145 146 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 160 161 160 161 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 764 772 748 756 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g005">Figure 5</xref>
###xml 774 775 758 759 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g005">5</xref>
###xml 938 945 922 929 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pbio-0030271-t001">Table 1</xref>
###xml 125 129 <span type="species:ncbi:10090">mice</span>
###xml 699 703 <span type="species:ncbi:10090">mice</span>
Unexpectedly, this initial screening revealed a potent effect of amphetamine derivatives on behavioral manifestations of DDD mice. High doses of d-amphetamine, d-methamphetamine, 4-chloro-amphetamine, phentermine, (+/-)-MDE ((+/-)-N-ethyl-3,4-methylenedioxyamphetamine HCl), (+)-MDE ((+)-N-ethyl-3,4-methylenedioxyamphetamine HCl), (-)-MDE ((-)-N-ethyl-3,4-methylenedioxyamphetamine HCl), (+/-)-MDA ((+/-)-3,4-methylenedioxyamphetamine HCl), (+/-)-6-OH-MDA ((+/-)-6-hydroxy-3,4-methylenedioxyamphetamine HCl), (+/-)-MDMA ((+/-)-3,4-methylenedioxymethamphetamine HCl), and (+)-MDMA ((+)-3,4-methylenedioxymethamphetamine HCl) were effective in reducing manifestations of akinesia and rigidity in DDD mice as detected in the catalepsy, grasping, and akinesia tests (Figure 5A-5C). However none of these drugs (with the exception of (+)-MDMA, see below) was effective in restoring movement control sufficiently to induce forward locomotion (Table 1).
###end p 24
###begin title 25
###xml 52 56 <span type="species:ncbi:10090">Mice</span>
DA-Independent Locomotor Effects of (+)-MDMA in DDD Mice
###end title 25
###begin p 26
###xml 139 147 139 147 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g005">Figure 5</xref>
###xml 149 150 149 150 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g005">5</xref>
###xml 243 250 243 250 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pbio-0030271-t001">Table 1</xref>
###xml 268 276 268 276 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g006">Figure 6</xref>
###xml 278 279 278 279 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g006">6</xref>
###xml 497 505 497 505 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g006">Figure 6</xref>
###xml 525 533 525 533 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g006">Figure 6</xref>
###xml 539 540 539 540 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g006">6</xref>
###xml 738 746 738 746 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g006">Figure 6</xref>
###xml 809 817 809 817 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g005">Figure 5</xref>
###xml 819 820 819 820 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g005">5</xref>
###xml 959 967 959 967 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g006">Figure 6</xref>
###xml 120 124 <span type="species:ncbi:10090">mice</span>
###xml 362 366 <span type="species:ncbi:10090">mice</span>
###xml 830 834 <span type="species:ncbi:10090">mice</span>
###xml 953 957 <span type="species:ncbi:10090">mice</span>
Among amphetamine derivatives, the most effective compound to counteract manifestations of akinesia and rigidity in DDD mice was (+)-MDMA (Figure 5A-5C). Thus, we tested (+)-MDMA in locomotor assay at even higher doses than those indicated in Table 1. As presented in Figure 6A-6C, (+)-MDMA at high doses was able to induce significant forward locomotion in DDD mice as measured by distance traveled in a locomotor activity test. This locomotor action of (+)-MDMA was observed in both cumulative (Figure 6A) and single dose (Figure 6B and 6C) treatments. In cumulative dosing experiments, a first treatment with 30 mg/kg of (+)-MDMA was not effective, but the subsequent administration of 60 mg/kg induced significant forward locomotion (Figure 6A) as well as reversal of other behavioral manifestations (see Figure 5A-5C) in DDD mice. Finally, testing of various single doses clearly showed a dose-dependence of the locomotor effect of (+)-MDMA in DDD mice (Figure 6C).
###end p 26
###begin p 27
###xml 273 274 273 274 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b07">7</xref>
###xml 275 277 275 277 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b38">38</xref>
###xml 278 280 278 280 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b40">40</xref>
###xml 667 675 667 675 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g006">Figure 6</xref>
###xml 909 917 909 917 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g006">Figure 6</xref>
###xml 1086 1095 1086 1095 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="sg001">Figure S1</xref>
###xml 1256 1265 1256 1265 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="sg002">Figure S2</xref>
###xml 299 303 <span type="species:ncbi:10090">mice</span>
###xml 591 595 <span type="species:ncbi:10090">mice</span>
###xml 802 806 <span type="species:ncbi:10090">mice</span>
###xml 1045 1049 <span type="species:ncbi:10090">mice</span>
###xml 1246 1250 <span type="species:ncbi:10090">mice</span>
The locomotor stimulating effect of amphetamine and its derivatives are classically thought to result from the massive efflux of DA from presynaptic DA terminals via a mechanism including displacement of DA from vesicular storage and reversal of DAT-mediated DA transport [7,38-40]. However, in DDD mice, there is only a minimal amount of DA remaining (<0.2%) and the lack of the DAT precludes the possibility of amphetamine-mediated DA efflux. In fact, in vivo microdialysis studies confirmed that (+)-MDMA, at the effective dose necessary to induce significant locomotor activation in DDD mice, did not produce any detectable increase in striatal extracellular DA (Figure 6D). Moreover, this locomotor stimulation by (+)-MDMA was not inhibited by simultaneous blockade of D1/D2 DA receptors when DDD mice were pretreated with a combination of the D1 and D2 DA receptor antagonists, SCH23390 and raclopride (Figure 6C). Similarly, this pretreatment did not prevent the effects of amphetamine and phentermine on the akinesia and rigidity in DDD mice in grasping and akinesia tests (see Figure S1). In contrast, the same D1/D2 DA receptor blockade completely abolished the locomotor stimulating effects of L-DOPA/carbidopa (50/50 mg/kg IP) in DDD mice (see Figure S2). Taken together, these data indicate that (+)-MDMA can affect movement control in a DA-independent manner [64] and, most importantly, provide a proof-of-principle that pharmacologic activation of nondopaminergic neuronal pathways may be sufficient to restore movement even in the absence of DA neurotransmission.
###end p 27
###begin p 28
###xml 166 168 166 168 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b64">38</xref>
###xml 341 343 341 343 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b65">65</xref>
###xml 413 415 413 415 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b66">66</xref>
###xml 416 418 416 418 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b67">67</xref>
###xml 555 557 555 557 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b38">38</xref>
###xml 704 706 704 706 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b68">68</xref>
###xml 933 935 931 933 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b69">69</xref>
###xml 1170 1171 1166 1167 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1276 1277 1266 1267 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1435 1436 1421 1422 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
###xml 239 243 <span type="species:ncbi:10090">mice</span>
###xml 593 597 <span type="species:ncbi:10090">mice</span>
###xml 787 791 <span type="species:ncbi:10090">mice</span>
###xml 818 822 <span type="species:ncbi:10090">mice</span>
###xml 1136 1140 <span type="species:ncbi:10090">mice</span>
###xml 1164 1168 <span type="species:ncbi:10090">mice</span>
###xml 1270 1274 <span type="species:ncbi:10090">mice</span>
###xml 1429 1433 <span type="species:ncbi:10090">mice</span>
It should be noted that the locomotor-stimulating effect of (+)-MDMA in DDD mice was observed only after high doses of the drug, which may be potentially neurotoxic [38]. However, the lack of the DAT renders dopaminergic neurons in DAT-KO mice significantly less sensitive to the neurotoxic effects of amphetamines, such as methamphetamine [65], as well as to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) [66,67]; thereby providing a unique opportunity to evaluate effects to large doses of amphetamines that would be impossible in normal animals [38]. It should be mentioned also that mice are generally less sensitive to MDMA neurotoxicity, particularly with regards to the serotonergic system [68]. Nevertheless, to directly evaluate the neurotoxic potential of MDMA in DAT-KO mice, we treated DAT-KO and WT mice with an established neurotoxic regimen of (+/-)-MDMA administration (4 injections of 20 mg/kg IP, every 2 h) [69] and assessed striatal tissue DA and 5-HT levels 7 d later. As might be expected, no significant differences in both DA and 5-HT levels were found between (+/-)-MDMA-treated and saline-treated DAT-KO mice (saline-treated DAT-KO mice (n = 6): DA, 0.53 +/- 0.03 ng/mg tissue; 5-HT, 0.36 +/- 0.03 ng/mg tissue; (+/-)-MDMA-treated DAT-KO mice (n = 7): DA, 0.58 +/- 0.04 ng/mg tissue; 5-HT, 0.40 +/- 0.02 ng/mg tissue), whereas the same regimen of treatment resulted in lethality of all treated WT mice (n = 7).
###end p 28
###begin p 29
###xml 272 280 272 280 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g006">Figure 6</xref>
###xml 435 437 435 437 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d-</italic>
###xml 453 455 453 455 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d-</italic>
###xml 472 480 472 480 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g006">Figure 6</xref>
###xml 884 886 884 886 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b38">38</xref>
Furthermore, to test whether the locomotor-stimulating effect of (+)-MDMA may be evident under certain conditions with lower (nonneurotoxic) doses of the drug, we co-administered (+)-MDMA with a minimally effective dose of L-DOPA/carbidopa (10/10 mg/kg, IP.). As shown in Figure 6E, a potent synergistic effect of L-DOPA/carbidopa and (+)-MDMA was observed. Furthermore, similar effects were observed with relatively moderate doses of d-amphetamine and d-methamphetamine (Figure 6F). Thus, a DA-independent locomotor effect of amphetamines can be markedly enhanced with additional dopaminergic stimulation. It is also important to note that in a similar experiment, MAO inhibitor deprenyl (5, 10, or 20 mg/kg IP) failed to potentiate the effects of L-DOPA/carbidopa (data not shown), indicating that this effect is not related to the well-known MAO-inhibiting action of amphetamines [38].
###end p 29
###begin title 30
###xml 67 71 <span type="species:ncbi:10090">Mice</span>
Nomifensine, but Not GBR12909 Affects Rigidity and Akinesia in DDD Mice
###end title 30
###begin p 31
###xml 497 499 497 499 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b42">42</xref>
###xml 801 809 801 809 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g007">Figure 7</xref>
###xml 815 816 815 816 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g007">7</xref>
###xml 893 901 893 901 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g007">Figure 7</xref>
###xml 907 908 907 908 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g007">7</xref>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
###xml 509 513 <span type="species:ncbi:10090">mice</span>
Finally, to evaluate the potential of other TA1 receptor ligands for their ability to affect motor control in DDD mice, we elected to compare the effects of two potent DAT blockers that have been shown to be markedly different with regards to their activity at TA1 receptor. It has been recently reported that the mixed DAT and NET inhibitor nomifensine can also potently activate TA1 receptor whereas the selective DAT blocker GBR12909 completely lacks the ability to interact with TA1 receptor [42]. In DDD mice, both nomifensine and GBR12909 at doses tested (cumulative treatment with 10 and 30 mg/kg IP) were not effective in inducing forward locomotion or reversing catalepsy (data not shown). Nevertheless, nomifensine significantly reduced akinesia and rigidity in grasping and akinesia tests (Figure 7A and 7B), whereas no such effects were observed with equivalent doses of GBR12909 (Figure 7A and 7B).
###end p 31
###begin title 32
Discussion
###end title 32
###begin p 33
###xml 71 75 <span type="species:ncbi:10090">mice</span>
###xml 536 540 <span type="species:ncbi:10090">mice</span>
In this study we demonstrate that inhibition of DA synthesis in DAT-KO mice represents a straightforward approach for developing an acute model of severe DA deficiency exhibiting a characteristic behavioral phenotype that can be utilized for testing perspective anti-PD treatments. Furthermore, these observations provide functional evidence for an important role of DAT-mediated recycling mechanism in the maintenance of intraneuronal DA. Finally, the novel DAT- and DA-independent locomotor action of amphetamines identified in these mice directly demonstrates the possibility of movement in a DA-independent manner.
###end p 33
###begin title 34
Role of DAT-Mediated DA Recycling in the Maintenance of Intraneuronal DA Storage
###end title 34
###begin p 35
###xml 995 997 995 997 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b13">13</xref>
###xml 1209 1211 1205 1207 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b70">70</xref>
###xml 554 558 <span type="species:ncbi:10090">mice</span>
DAT is commonly known as a major regulator of the duration and intensity of extracellular DA signaling. However the important role of DAT in the control and maintenance of the intraneuronal DA storage pool frequently remains overlooked. It is generally assumed that the intraneuronal storage of DA is replenished primarily from newly synthesized DA with some contribution from recycled DA. However, several lines of evidence support a predominant role of DAT-mediated recycling of DA for the maintenance of the large storage pool in DA terminals. First, mice lacking the DAT display dramatically decreased (20-fold) striatal tissue DA content, that mostly represents intraneuronal DA concentrations. Second, as we demonstrate in the present study, the remaining DA in all compartments is extremely sensitive to TH inhibition. Furthermore, pharmacologic studies have shown that significant DA depletion may occur after administration of DAT inhibitors, particularly after chronic drug treatment [13]. Importantly, in the frontal cortex, where DAT levels are normally low in comparison to the striatum, tissue DA concentration is also low and can be more significantly affected than in the striatum by alphaMT [70]. It is likely that the newly synthesized DA does not contribute directly to the large storage pool of DA in nigrostriatal terminals, but rather contributes to it indirectly via released and recycled DA. Thus, a cooperative function of both DA synthesis and transporter-mediated recycling processes is necessary for the maintenance of normal presynaptic monoamine concentrations.
###end p 35
###begin title 36
###xml 14 19 <span type="species:ncbi:10090">Mouse</span>
###xml 76 80 <span type="species:ncbi:10090">Mice</span>
A Novel Acute Mouse Model of Severe DA Deficiency, DA-Depleted DAT-KO (DDD) Mice
###end title 36
###begin p 37
###xml 95 100 <span type="species:ncbi:10090">mouse</span>
###xml 136 140 <span type="species:ncbi:10090">mice</span>
###xml 194 198 <span type="species:ncbi:10090">mice</span>
###xml 419 423 <span type="species:ncbi:10090">mice</span>
###xml 487 491 <span type="species:ncbi:10090">mice</span>
###xml 683 687 <span type="species:ncbi:10090">mice</span>
###xml 906 910 <span type="species:ncbi:10090">mice</span>
By using a combination of genetic and pharmacologic approaches we have developed a novel acute mouse model of severe DA deficiency, DDD mice. The lack of an active recycling mechanism in DAT-KO mice results in a profound depletion of intraneuronal concentrations of DA leaving the remaining DA entirely dependent on ongoing synthesis. As a result, inhibition of DA synthesis essentially eliminates striatal DA in these mice leading to the extreme behavioral manifestations. In fact, DDD mice demonstrate a unique set of behaviors that reproduces symptoms of PD with high fidelity. Thus, the lack of DA combined with the striking and highly reproducible behavioral phenotype in these mice can be used as an excellent tool to evaluate the potential of drugs that can affect locomotion in a DA-independent manner. Furthermore, by adapting the dose of alphaMT to produce various degrees of DA depletion, these mice can also be employed to find novel approaches to restore movement under conditions of partially impaired DA transmission that might be more relevant to most PD cases.
###end p 37
###begin p 38
###xml 812 814 812 814 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b72">72</xref>
Several rodent models have been developed to understand pathological processes leading to PD and/or to screen for novel therapeutic strategies [29,30,34-36,71]. These models either recapitulate the loss of DA through pharmacologic or genetic manipulation, or recapitulate the neurodegenerative process through administration of selective neurotoxins and, recently, through mutations of specific proteins. However, in many of these models only incomplete and highly variable levels of DA depletion are achieved often precluding an accurate recapitulation of the neurological manifestations of PD. This poor behavioral expression of PD-related behaviors generally results in high level of false-positive results in drug screening tests in general, and particularly in those attempted to identify non-DA therapies [72].
###end p 38
###begin p 39
###xml 69 71 69 71 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b73">73</xref>
###xml 72 74 72 74 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b74">74</xref>
###xml 172 173 172 173 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b03">3</xref>
###xml 174 176 174 176 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b75">75</xref>
###xml 177 179 177 179 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b80">81</xref>
###xml 583 585 583 585 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b77">77</xref>
###xml 586 588 586 588 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b81">81</xref>
###xml 726 727 726 727 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b03">3</xref>
###xml 728 730 728 730 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b76">76</xref>
###xml 731 733 731 733 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b79">79</xref>
###xml 1259 1261 1259 1261 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b81">81</xref>
###xml 1384 1386 1384 1386 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b11">11</xref>
###xml 1387 1389 1387 1389 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b13">13</xref>
###xml 1573 1574 1573 1574 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b03">3</xref>
###xml 1575 1577 1575 1577 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b76">76</xref>
###xml 1683 1684 1683 1684 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b03">3</xref>
###xml 1685 1687 1685 1687 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b76">76</xref>
###xml 1688 1690 1688 1690 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b81">81</xref>
###xml 1848 1850 1848 1850 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b75">75</xref>
###xml 1851 1853 1851 1853 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b80">80</xref>
###xml 1886 1893 1886 1893 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="pbio-0030271-t001">Table 1</xref>
###xml 2273 2275 2273 2275 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b82">82</xref>
###xml 2344 2346 2344 2346 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b83">83</xref>
###xml 22 27 <span type="species:ncbi:10090">mouse</span>
###xml 164 168 <span type="species:ncbi:10090">mice</span>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
###xml 427 431 <span type="species:ncbi:10090">mice</span>
###xml 638 642 <span type="species:ncbi:10090">mice</span>
###xml 720 724 <span type="species:ncbi:10090">mice</span>
###xml 1088 1092 <span type="species:ncbi:10090">mice</span>
###xml 1209 1213 <span type="species:ncbi:10090">mice</span>
###xml 1305 1309 <span type="species:ncbi:10090">mice</span>
###xml 1520 1524 <span type="species:ncbi:10090">mice</span>
###xml 1677 1681 <span type="species:ncbi:10090">mice</span>
###xml 1880 1884 <span type="species:ncbi:10090">mice</span>
###xml 2006 2010 <span type="species:ncbi:10090">mice</span>
###xml 2027 2031 <span type="species:ncbi:10090">mice</span>
###xml 2198 2202 <span type="species:ncbi:10090">mice</span>
Among several genetic mouse models of DA deficiency available today [73,74], the most effective was developed by inactivation of TH in DA neurons (DA-deficient [DD mice]) [3,75-81]. DD mice have provided important insights into the role of DA in movement control, feeding, and reward. This mutation results in severely impaired movement and feeding, which become apparent at 10 d and leads to death by 30 d. To maintain viable mice with the ability to move and feed requires daily treatment with L-DOPA, which results in an oscillation of striatal DA from about 1% to 10% over 24 h [77,81]. Many behavioral manifestations observed in DDD mice in this study, such as rigidity and akinesia, were observed previously in DD mice [3,76,79]. Importantly, both of these models showed temporal locomotor reactivity to stress and demonstrated normal righting reflex and ability to swim, indicating that certain movements may occur in a DA-independent manner. Despite these similarities, some important differences were noted between these two genetic models of severe DA dysfunction. In DD mutant mice, a lack of TH resulting in permanently decreased DA signaling, as well as daily treatments with L-DOPA render these mice extremely supersensitive to DA stimulations [81], whereas excessive DA signaling in DAT-KO mice results in compensatory down-regulation (but nonuniform) of DA receptors [11,13]. This may explain why certain behavioral manifestations of DA deficiency such as rigidity and akinesia may be more robust in DDD mice, whereas tremor was not observed in DD mutants [3,76]. Furthermore, efficacy of L-DOPA and DA agonists are remarkably higher in DD in comparison to DDD mice [3,76,81]. Additionally, several other drugs, such as caffeine and N-methyl-D-aspartate receptor antagonist MK-801, that are able to induce locomotion in DD mutants [75,80] are not effective in DDD mice (Table 1). In fact, down-regulation of DA receptor responsiveness combined with the extreme level of DA depletion in DDD mice may favor these mice as a very conservative approach for evaluating drugs that can affect locomotion in a DA-independent manner. Furthermore, rapid and effective elimination of DA in DDD mice may provide a simple in vivo approach to study DA receptor signaling [82] and/or to define neuronal circuitry involved in locomotor control [83].
###end p 39
###begin title 40
DA-Independent Locomotor Action of Amphetamines
###end title 40
###begin p 41
###xml 38 39 38 39 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 137 138 137 138 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 519 521 519 521 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b76">76</xref>
###xml 537 538 537 538 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 1529 1531 1529 1531 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b84">84</xref>
###xml 1584 1586 1584 1586 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b85">85</xref>
###xml 1614 1616 1614 1616 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b64">64</xref>
###xml 33 37 <span type="species:ncbi:10090">mice</span>
###xml 131 135 <span type="species:ncbi:10090">mice</span>
###xml 364 368 <span type="species:ncbi:10090">mice</span>
###xml 531 535 <span type="species:ncbi:10090">mice</span>
###xml 877 881 <span type="species:ncbi:10090">mice</span>
###xml 1276 1280 <span type="species:ncbi:10090">mice</span>
###xml 1523 1527 <span type="species:ncbi:10116">rats</span>
###xml 1578 1582 <span type="species:ncbi:10116">rats</span>
Intriguingly, in both DD and DDD mice d-amphetamine was effective in restoring at least some aspects of locomotor behaviors. In DD mice, d-amphetamine (5 mg/kg IP) induced potent locomotor activation essentially up to the levels observed in WT controls. At the same time, a second treatment 2 h later by the same dose of the drug failed to induce locomotion in DD mice suggesting that this effect is dependent upon residual (after L-DOPA administration) DA which might be depleted by the first treatment with the drug [76]. In DDD mice, d-amphetamine itself was not able to induce forward locomotion at doses up to 60 mg/kg, but it produced significant effects on other manifestations of DA deficiency. Moreover, co-administration of relatively moderate doses of amphetamine (15 and 20 mg/kg) with a subthreshold dose of L-DOPA resulted in a marked locomotor activation of DDD mice. Thus, some DA tone seems to be necessary to express the full magnitude of locomotor activation by amphetamine, but it is evident that there is a DA-independent component of action that contributes to the overall effect of the drug. Further evidence for this idea relates to the fact that many other amphetamine derivatives are also active in reversing certain behavioral manifestations in DDD mice. Strikingly, both single and repeated treatment with (+)-MDMA was effective in inducing forward locomotion essentially without any contribution of DA. It is important to note that a potent anticataleptic effect of MDMA in haloperidol-treated rats [84] and antiakinetic effects in 6-OH-DA-lesioned rats [85] and MPTP-treated monkeys [64] have been recently reported. The present observations support these findings and suggest that these actions are not unique to MDMA but may be extended to other amphetamines. Further characterization of these unexpected effects of amphetamines may provide a novel framework in the search for potential anti-Parkinsonian drugs.
###end p 41
###begin p 42
###xml 232 233 232 233 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b07">7</xref>
###xml 234 236 234 236 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b10">10</xref>
###xml 237 239 237 239 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b12">12</xref>
###xml 240 242 240 242 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b38">38</xref>
###xml 243 245 243 245 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b39">39</xref>
###xml 418 420 418 420 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b40">40</xref>
###xml 815 817 815 817 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b38">38</xref>
###xml 818 820 818 820 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b40">40</xref>
###xml 821 823 821 823 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b86">86</xref>
###xml 1371 1373 1367 1369 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b38">38</xref>
###xml 1572 1574 1568 1570 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b10">10</xref>
###xml 1575 1577 1571 1573 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b38">38</xref>
###xml 1578 1580 1574 1576 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b83">83</xref>
###xml 301 305 <span type="species:ncbi:10090">mice</span>
###xml 642 646 <span type="species:ncbi:10090">mice</span>
###xml 1104 1108 <span type="species:ncbi:10090">mice</span>
###xml 1265 1269 <span type="species:ncbi:10090">mice</span>
###xml 1468 1472 <span type="species:ncbi:10090">mice</span>
Amphetamine derivatives are known mainly as indirect enhancers of monoaminergic (DA, NE, and 5-HT) transmission via complex interactions with the plasma membrane monoamine transporters and the vesicular storage of these monoamines [7,10,12,38,39]. It should be reiterated that a lack of DAT in DAT-KO mice excludes the possibility of major effects of amphetamines on DAT-mediated DA efflux from presynaptic DA stores [40]. Furthermore, a blockade of D1/D2 DA receptors was ineffective in preventing the locomotor stimulating action of (+)-MDMA. Thus, it is virtually impossible that the observed effects of MDMA and other amphetamines in DDD mice are directly related to DA transmission. Although it is possible that this effect may be due to transporter-mediated action of amphetamines on NE or 5-HT transmission [38,40,86], it should be noted that among several NE- and 5-HT-related drugs tested (desipramine, clonidine, the NE precursor DOPS, fluoxetine, 5-methoxy-N,N-dimethyltryptamine, 5-methyl-N,N-dimethyltryptamine, alpha-ethyltryptamine, and 5-HT1B agonist RU24969), none were effective in DDD mice in tests of forward locomotion or akinesia and rigidity (data not shown). Similarly, no locomotor effect of MAO-A or MAO-B inhibitors was observed in these mice, indicating that the locomotor effect of amphetamines may not be explained by MAO-inhibitory action [38]. Furthermore, it should be underlined that locomotor actions of amphetamines observed in DDD mice occur at doses that are much higher than necessary to induce classic transporter-mediated effects [10,38,83].
###end p 42
###begin p 43
###xml 121 123 118 120 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b87">87</xref>
###xml 283 285 277 279 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b63">63</xref>
###xml 500 502 491 493 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b42">42</xref>
###xml 503 505 494 496 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b88">88</xref>
###xml 696 698 687 689 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b43">43</xref>
###xml 699 701 690 692 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b44">44</xref>
###xml 702 704 693 695 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b63">63</xref>
###xml 769 771 760 762 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b42">42</xref>
###xml 1067 1069 1058 1060 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b42">42</xref>
###xml 906 910 <span type="species:ncbi:10090">mice</span>
###xml 1111 1115 <span type="species:ncbi:10090">mice</span>
###xml 1185 1189 <span type="species:ncbi:10090">mice</span>
###xml 1484 1488 <span type="species:ncbi:10090">mice</span>
Amphetamines share close structural similarity with an endogenous trace amine of unknown function beta-phenylethylamine [87]. Amphetamines and beta-phenylethylamine similarly interact with the plasma membrane monoamine transporters to elevate extracellular monoamine concentrations [63]. Intriguingly, recent evidence indicates that many amphetamine derivatives, including MDMA, may also act directly as agonists of trace amine TA1 receptors, that are known to be activated by beta-phenylethylamine [42,88]. Several members of the family of trace amine receptors have been identified, however little is known about the pharmacology and functional role of these receptors in mammalian physiology [43,44,63]. It is reasonable to suggest that activation of TA1 receptors [42] or other trace amine receptors may provide a potential mechanism for DA-independent locomotor effect of MDMA and amphetamines in DDD mice. In line with this hypothesis, we observed that the DAT blocker nomifensine that can activate TA1 receptor, but not GBR12909 which is devoid this activity [42], is able to affect motor control in DDD mice. It should be noted, however, that in our initial exploration in DDD mice, we did not observe clear locomotor effects for any trace amine tested; but only a few doses, routes of administration, and combinations with enzyme inhibitors were investigated. Further detailed investigations will be needed to clarify the mechanism of locomotor action of amphetamines in DDD mice.
###end p 43
###begin title 44
Conclusions
###end title 44
###begin p 45
###xml 231 235 <span type="species:ncbi:10090">mice</span>
In summary, these results provide additional functional evidence for the critical role of DAT in the maintenance of DA storage in presynaptic terminals. Rapid and effective abolishment of DA by inhibition of DA synthesis in DAT-KO mice provides a novel approach to develop severe DA deficiency that might be used to identify neuronal mechanisms involved in motor control in the absence of DA. Amphetamines are capable of affecting neuronal systems involved in motor control through mechanisms independent of DAT, in particular, and DA in general.
###end p 45
###begin title 46
Materials and Methods
###end title 46
###begin title 47

###end title 47
###begin title 48
Animals
###end title 48
###begin p 49
###xml 52 54 52 54 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b11">11</xref>
###xml 519 521 519 521 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b60">60</xref>
###xml 7 11 <span type="species:ncbi:10090">mice</span>
###xml 364 368 <span type="species:ncbi:10090">mice</span>
###xml 513 517 <span type="species:ncbi:10090">mice</span>
DAT-KO mice were generated as previously described [11]. Animal care was in accordance with the Guide for Care and Use of Laboratory Animals (National Institutes of Health publication #865-23, Bethesda, Maryland, United States) with an approved protocol from the Duke University Institutional Animal Care and Use Committee. C57BL/6J x 129Sv/J hybrid WT and DAT-KO mice, 3-5 mo old, of both sexes were used. None of animals used in these studies had the neurodegenerative phenotype sporadically observed in DAT-KO mice [60].
###end p 49
###begin title 50
Drugs
###end title 50
###begin p 51
Drugs or saline (0.9% NaCl) were administered intraperitoneally (IP) or subcutaneously (SC) in a volume of 10 ml/kg. The drugs were either from Sigma (St. Louis, Missouri, United States) or supplied by the National Institute of Drug Abuse (NIDA). Drugs provided by the NIDA Drug Supply Program included: (+/-)-MDMA, (+)-MDMA, (+/-)-6-OH-MDA, (+/-)-MDA, (+/-)-MDE, (+)-MDE, (-)-MDE, and AET (alpha-ethyl-tryptamine acetate).
###end p 51
###begin title 52
Neurochemical assessments
###end title 52
###begin p 53
###xml 186 187 186 187 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b08">8</xref>
###xml 381 383 381 383 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b50">50</xref>
###xml 278 282 <span type="species:ncbi:10090">mice</span>
Striatal tissue contents of DA and frontal cortical tissue levels of NE were assessed using HPLC-EC (high performance liquid chromatography with electrochemical detection) as described [8]. In vivo microdialysis measurements of striatal extracellular DA levels in freely moving mice were performed at least 24 h after implantation of a microdialysis probe as described previously [50]. Dialysate samples were assayed for DA using HPLC-EC.
###end p 53
###begin title 54
Behavioral methods
###end title 54
###begin p 55
###xml 188 190 188 190 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b83">83</xref>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 360 364 <span type="species:ncbi:10090">mice</span>
Locomotor activity of littermate WT and DAT-KO mice was measured in an Omnitech CCDigiscan (Accuscan Instruments, Columbus, Ohio United States) activity monitor under bright illumination [83]. All behavioral experiments were performed between 10:00 AM and 5:00 PM. Activity was measured at 5-min intervals. To evaluate the effects of drugs on motor behaviors, mice were placed into activity monitor chambers (20 x 20 cm) for 30 min and then treated with alphaMT (250 mg/kg IP). A drug or combination of drugs were injected 1 h after alphaMT administration, and various parameters of locomotor activity were monitored for up to 3 h. In cumulative dosing experiments, animals were treated with increasing doses of drugs after a 1-h interval.
###end p 55
###begin p 56
###xml 197 199 197 199 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b57">57</xref>
###xml 475 477 475 477 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b53">53</xref>
###xml 712 714 712 714 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b58">58</xref>
###xml 873 875 873 875 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b57">57</xref>
###xml 937 939 937 939 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b54">54</xref>
###xml 1132 1134 1132 1134 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b89">89</xref>
###xml 1739 1741 1739 1741 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="pbio-0030271-b55">55</xref>
###xml 27 32 <span type="species:ncbi:10090">mouse</span>
###xml 382 387 <span type="species:ncbi:10090">mouse</span>
###xml 527 532 <span type="species:ncbi:10090">mouse</span>
###xml 809 814 <span type="species:ncbi:10090">mouse</span>
###xml 908 912 <span type="species:ncbi:10090">mice</span>
###xml 1300 1305 <span type="species:ncbi:10090">mouse</span>
###xml 1339 1343 <span type="species:ncbi:10090">mice</span>
For the akinesia test, the mouse is held by the tail so that it is standing on forelimbs only and moving on its own. The number of steps taken with both forelimbs was recorded during a 30-s trial [57]. The presence of catalepsy was determined and measured by placing the animal's forepaws on a horizontal wooden bar (0.7 cm in diameter), 4 cm above the tabletop. The time until the mouse removed both forepaws from the bar was recorded, with a maximum cut-off time of 3 min [53]. In the grasping test of muscular rigidity, the mouse is suspended by its forelimbs on a metal rod (diameter: 0.25 cm) positioned approximately 20 cm above the table. The time the animal remains on the rod (maximum 1 min) was noted [58]. To assess rigidity in a bracing task, the number of steps taken with each forelimb when the mouse is pushed sideways over a distance of 50 cm was recorded [57]. Tremor was scored visually in mice using the rating scale [54]: 0, no tremor; 1, occasional isolated twitches; 2, moderate or intermittent tremor associated with short periods of calm; and 3, pronounced continuous tremor. Ptosis was scored as described [89]: 4, eyes completely closed; 2, half-open eyes; and 0, wide-open eyes; with 1 and 3 indicating intermediate values. The righting reflex was evaluated by turning the mouse onto its back five times. Normal mice immediately turn themselves over, to right themselves onto all four feet. Righting reflex was scored as follows: 0, no impairment; 1, on side one to two times; 2, on side three to four times; 3, on side five times; 4, on back one to two times; 5, on back three to four times; 6, on back five times; 7, sluggish when placed on back; and 8, righting response absent when on back and tail pinched [55].
###end p 56
###begin title 57
Data analysis
###end title 57
###begin p 58
###xml 81 82 79 80 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 204 205 202 203 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
The data are presented as mean +/- SEM and analyzed using a two-tailed Student's t-test and one-way analysis of variance (ANOVA) followed by Dunnet's multiple comparison test or a two-tailed Mann-Whitney U test when appropriate.
###end p 58
###begin title 59
Supporting Information
###end title 59
###begin title 60
###xml 119 123 <span type="species:ncbi:10090">Mice</span>
D1/D2 DA Receptor Blockade Does Not Prevent the Effects of Amphetamine and Phentermine on Rigidity and Akinesia in DDD Mice
###end title 60
###begin p 61
(4.8 MB TIF).
###end p 61
###begin p 62
Click here for additional data file.
###end p 62
###begin title 63
###xml 96 100 <span type="species:ncbi:10090">Mice</span>
D1/D2 DA Receptor Blockade Prevents the Locomotor Stimulating Effect of L-DOPA/Carbidopa in DDD Mice
###end title 63
###begin p 64
(4.4 MB TIF).
###end p 64
###begin p 65
Click here for additional data file.
###end p 65
###begin title 66
###xml 28 32 <span type="species:ncbi:10090">mice</span>
Behavioral Phenotype of DDD mice
###end title 66
###begin p 67
(10 MB MOV).
###end p 67
###begin p 68
Click here for additional data file.
###end p 68
###begin p 69
This work was supported in part by grants from the National Institutes of Health NS-19576 and MH-40159.
###end p 69
###begin p 70
###xml 0 20 0 20 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 70
###begin p 71
###xml 0 21 0 21 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Author contributions.</bold>
Author contributions. TDS, MGC, and RRG conceived and designed the experiments. TDS and RRG performed the experiments. TDS, JMB, LSB, WCW, and RRG analyzed the data. WCW and MGC contributed reagents/materials/analysis tools. TDS, JMB, LSB, WCW, MGC, and RRG wrote the paper.
###end p 71
###begin title 72
References
###end title 72
###begin article-title 73
Biochemistry of catecholamines
###end article-title 73
###begin article-title 74
Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence
###end article-title 74
###begin article-title 75
###xml 19 23 <span type="species:ncbi:10090">mice</span>
Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic
###end article-title 75
###begin article-title 76
Localization of monoamines in the lower brain stem
###end article-title 76
###begin article-title 77
###xml 70 73 <span type="species:ncbi:10116">rat</span>
The organization of the ascending catecholamine neuron systems in the rat brain as revealed by the glyoxylic acid fluorescence method
###end article-title 77
###begin article-title 78
###xml 53 56 <span type="species:ncbi:10116">rat</span>
Stereotaxic mapping of the monoamine pathways in the rat brain
###end article-title 78
###begin article-title 79
Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action
###end article-title 79
###begin article-title 80
Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine
###end article-title 80
###begin article-title 81
Dopamine receptors: From structure to function
###end article-title 81
###begin article-title 82
Neurotransmitter transporters as molecular targets for addictive drugs
###end article-title 82
###begin article-title 83
###xml 63 67 <span type="species:ncbi:10090">mice</span>
Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter
###end article-title 83
###begin article-title 84
Profound neuronal plasticity in response to inactivation of the dopamine transporter
###end article-title 84
###begin article-title 85
Monoamine transporters: From genes to behavior
###end article-title 85
###begin article-title 86
Biochemical and pharmacological aspects of Parkinsonism
###end article-title 86
###begin article-title 87
L-DOPA: From a biologically inactive amino acid to a successful therapeutic agent
###end article-title 87
###begin article-title 88
Functional neuroanatomy of the basal ganglia in Parkinson's disease
###end article-title 88
###begin article-title 89
The basal ganglia
###end article-title 89
###begin article-title 90
Description of Parkinson's disease as a clinical syndrome
###end article-title 90
###begin article-title 91
Deep brain stimulation for Parkinson's disease
###end article-title 91
###begin article-title 92
Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells
###end article-title 92
###begin article-title 93
Medical treatment of Parkinson's disease
###end article-title 93
###begin article-title 94
3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists
###end article-title 94
###begin article-title 95
[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia.]
###end article-title 95
###begin article-title 96
Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease
###end article-title 96
###begin article-title 97
Pharmacology of dopamine agonists in the treatment of Parkinson's disease
###end article-title 97
###begin article-title 98
Chemical neuroanatomy of the basal ganglia-normal and in Parkinson's disease
###end article-title 98
###begin article-title 99
Potential nondopaminergic drugs for Parkinson's disease
###end article-title 99
###begin article-title 100
Progress in pursuit of therapeutic A2A antagonists: The adenosine A2A receptor selective antagonist KW6002: Research and development toward a novel nondopaminergic therapy for Parkinson's disease
###end article-title 100
###begin article-title 101
Depletion of dopamine in the striatum as an experimental model of Parkinsonism: direct effects and adaptive mechanisms
###end article-title 101
###begin article-title 102
Parkinson's disease: Studies with an animal model
###end article-title 102
###begin article-title 103
###xml 29 34 <span type="species:ncbi:9606">human</span>
###xml 43 48 <span type="species:ncbi:9606">human</span>
MPTP-induced parkinsonism in human and non-human primates-clinical and experimental aspects
###end article-title 103
###begin article-title 104
Development of new pharmacological approaches in Parkinson's disease
###end article-title 104
###begin article-title 105
###xml 103 106 <span type="species:ncbi:9606">man</span>
Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man
###end article-title 105
###begin article-title 106
New animal models for Parkinson's disease
###end article-title 106
###begin article-title 107
Parkinson's disease: Mechanisms and models
###end article-title 107
###begin article-title 108
###xml 8 13 <span type="species:ncbi:10090">mouse</span>
Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect
###end article-title 108
###begin article-title 109
###xml 47 51 <span type="species:ncbi:10090">mice</span>
Release and elimination of dopamine in vivo in mice lacking the dopamine transporter: functional consequences
###end article-title 109
###begin article-title 110
Amphetamine: Effects on catecholamine systems and behavior
###end article-title 110
###begin article-title 111
Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport
###end article-title 111
###begin article-title 112
###xml 45 49 <span type="species:ncbi:10090">mice</span>
Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter
###end article-title 112
###begin article-title 113
Dissociation of rewarding and dopamine transporter-mediated properties of amphetamine
###end article-title 113
###begin article-title 114
###xml 149 152 <span type="species:ncbi:10116">rat</span>
Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor
###end article-title 114
###begin article-title 115
Following the trace of elusive amines
###end article-title 115
###begin article-title 116
Trace amine receptors as targets for novel therapeutics: Legend, myth and fact
###end article-title 116
###begin article-title 117
Drugs acting through dopamine release
###end article-title 117
###begin article-title 118
Monoamine precursors and analogues
###end article-title 118
###begin article-title 119
###xml 115 119 <span type="species:ncbi:10090">mice</span>
Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice
###end article-title 119
###begin article-title 120
Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease
###end article-title 120
###begin article-title 121
###xml 166 170 <span type="species:ncbi:10090">mice</span>
Synergistic interactions between muscarinic antagonists, adrenergic agonists and NMDA antagonists with respect to locomotor stimulatory effects in monoamine-depleted mice
###end article-title 121
###begin article-title 122
###xml 79 83 <span type="species:ncbi:10090">mice</span>
Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice
###end article-title 122
###begin article-title 123
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice lacking the norepinephrine transporter are supersensitive to psychostimulants
###end article-title 123
###begin article-title 124
###xml 149 153 <span type="species:ncbi:10090">mice</span>
Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice
###end article-title 124
###begin article-title 125
###xml 158 162 <span type="species:ncbi:10090">mice</span>
Neurotensin gene expression and behavioral responses following administration of psychostimulants and antipsychotic drugs in dopamine D(3) receptor deficient mice
###end article-title 125
###begin article-title 126
The pharmacology of N-carbamoyl-2-(2,6-dichlorophenyl)acetamidine hydrochloride (LON-954) a new tremorogenic agent
###end article-title 126
###begin article-title 127
###xml 144 148 <span type="species:ncbi:10090">mice</span>
A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice
###end article-title 127
###begin article-title 128
Control of repetitive lip and finger movements in Parkinson's disease: Influence of external timing signals and simultaneous execution on motor performance
###end article-title 128
###begin article-title 129
Validation of a rodent model of Parkinson's Disease: Evidence of a therapeutic window for oral Sinemet
###end article-title 129
###begin article-title 130
###xml 80 83 <span type="species:ncbi:10116">rat</span>
Hypokinesia, rigidity, and tremor induced by hypothalamic 6-OHDA lesions in the rat
###end article-title 130
###begin article-title 131
###xml 60 64 <span type="species:ncbi:10090">mice</span>
Restoration of norepinephrine and reversal of phenotypes in mice lacking dopamine beta-hydroxylase
###end article-title 131
###begin article-title 132
Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons
###end article-title 132
###begin article-title 133
Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems
###end article-title 133
###begin article-title 134
Is stimulation of both D1 and D2 receptors necessary for the expression of dopamine-mediated behaviors?
###end article-title 134
###begin article-title 135
Dopamine transporter-dependent and -independent actions of trace amine beta-phenylethylamine
###end article-title 135
###begin article-title 136
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates
###end article-title 136
###begin article-title 137
###xml 85 89 <span type="species:ncbi:10090">mice</span>
Role of dopamine transporter in methamphetamine-induced neurotoxicity: Evidence from mice lacking the transporter
###end article-title 137
###begin article-title 138
###xml 79 83 <span type="species:ncbi:10090">mice</span>
Dopamine transporter is required for in vivo MPTP neurotoxicity: Evidence from mice lacking the transporter
###end article-title 138
###begin article-title 139
Dopamine transporters and neuronal injury
###end article-title 139
###begin article-title 140
Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function
###end article-title 140
###begin article-title 141
###xml 67 72 <span type="species:ncbi:10090">mouse</span>
Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse
###end article-title 141
###begin article-title 142
Pharmacology of mesocortical dopamine neurons
###end article-title 142
###begin article-title 143
The rotenone model of Parkinson's disease: genes, environment and mitochondria
###end article-title 143
###begin article-title 144
The implementation of acute versus chronic animal models for treatment discovery in Parkinson's disease
###end article-title 144
###begin article-title 145
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 110 115 <span type="species:ncbi:10090">mouse</span>
Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: Potential mouse model for parkinsonism
###end article-title 145
###begin article-title 146
###xml 11 16 <span type="species:ncbi:10090">mouse</span>
Transgenic mouse models of dopamine deficiency
###end article-title 146
###begin article-title 147
###xml 102 106 <span type="species:ncbi:10090">mice</span>
Adenosine receptor blockade reverses hypophagia and enhances locomotor activity of dopamine-deficient mice
###end article-title 147
###begin article-title 148
###xml 39 43 <span type="species:ncbi:10090">mice</span>
Feeding behavior in dopamine-deficient mice
###end article-title 148
###begin article-title 149
###xml 46 50 <span type="species:ncbi:10090">mice</span>
Induction of stereotypy in dopamine-deficient mice requires striatal D1 receptor activation
###end article-title 149
###begin article-title 150
Reward without dopamine
###end article-title 150
###begin article-title 151
The role of dopamine in learning, memory, and performance of a water escape task
###end article-title 151
###begin article-title 152
Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists
###end article-title 152
###begin article-title 153
###xml 19 23 <span type="species:ncbi:10090">mice</span>
Dopamine-deficient mice are hypersensitive to dopamine receptor agonists
###end article-title 153
###begin article-title 154
Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade
###end article-title 154
###begin article-title 155
Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity
###end article-title 155
###begin article-title 156
###xml 33 37 <span type="species:ncbi:10116">rats</span>
Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect?
###end article-title 156
###begin article-title 157
###xml 87 91 <span type="species:ncbi:10116">rats</span>
Is the Ecstasy-induced ipsilateral rotation in 6-hydroxydopamine unilaterally lesioned rats dopamine independent?
###end article-title 157
###begin article-title 158
Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: Cellular and molecular mechanisms
###end article-title 158
###begin article-title 159
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Does phenylethylamine act as an endogenous amphetamine in some patients?
###end article-title 159
###begin article-title 160
Trace amines: Identification of a family of mammalian G protein-coupled receptors
###end article-title 160
###begin article-title 161
###xml 147 151 <span type="species:ncbi:10116">rats</span>
Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? I. "Neuroleptic activity spectra" for rats
###end article-title 161
###begin title 162
Abbreviations
###end title 162
###begin p 163
serotonin
###end p 163
###begin p 164
alpha-methyl-p-tyrosine
###end p 164
###begin p 165
dopamine
###end p 165
###begin p 166
dopamine transporter
###end p 166
###begin p 167
###xml 30 34 <span type="species:ncbi:10090">mice</span>
dopamine transporter knockout mice
###end p 167
###begin p 168
###xml 19 23 <span type="species:ncbi:10090">mice</span>
dopamine-deficient mice
###end p 168
###begin p 169
###xml 26 30 <span type="species:ncbi:10090">mice</span>
dopamine-deficient DAT-KO mice
###end p 169
###begin p 170
intraperitoneal
###end p 170
###begin p 171
###xml 0 1 0 1 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">L</italic>
L-aromatic acid decarboxylase
###end p 171
###begin p 172
monoamine oxidase
###end p 172
###begin p 173
norepinephrine
###end p 173
###begin p 174
norepinephrine transporter
###end p 174
###begin p 175
Parkinson disease
###end p 175
###begin p 176
subcutaneous
###end p 176
###begin p 177
Substantia Nigra Pars Compacta
###end p 177
###begin p 178
trace amine 1 receptor
###end p 178
###begin p 179
tyrosine hydroxylase
###end p 179
###begin p 180
vesicular monoamine transporter-2
###end p 180
###begin p 181
ventral tegmental area
###end p 181
###begin p 182
wild-type
###end p 182
###begin p 183
###xml 154 159 <span type="species:ncbi:10090">mouse</span>
Citation: Sotnikova TD, Beaulieu JM, Barak LS, Wetsel WC, Caron MG, et al. (2005) Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol 3(8): e271.
###end p 183
###begin title 184
Figures and Table
###end title 184
###begin title 185
###xml 62 66 <span type="species:ncbi:10090">Mice</span>
alphaMT Induces Severe DA Depletion in the Striatum of DAT-KO Mice
###end title 185
###begin p 186
###xml 86 87 86 87 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 177 178 177 178 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 197 198 197 198 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
(A) Tissue levels of DA in the striatum of saline-treated control WT and DAT-KO mice (n = 7 per group). Striatal levels of DA were significantly lower in DAT-KO versus WT mice (p < 0.05, Student's t-test).
###end p 186
###begin p 187
###xml 98 99 94 95 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 280 281 272 273 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 466 467 454 455 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 500 501 488 489 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 92 96 <span type="species:ncbi:10090">mice</span>
###xml 232 236 <span type="species:ncbi:10090">mice</span>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
(B) Dynamics of the effect of alphaMT (250 mg/kg IP) on striatal tissue DA in WT and DAT-KO mice (n = 5-8 per group). DA levels were significantly lower versus control values at all the time points after alphaMT treatment in DAT-KO mice and 2-24 hours after treatment in WT mice (p < 0.05, one-way ANOVA followed by Dunnet's multiple comparison test). The magnitude of the effect was significantly different between genotypes from 1 to 16 h after alphaMT injection (p < 0.05, two-tailed Mann-Whitney U test).
###end p 187
###begin p 188
###xml 84 85 84 85 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
(C) Tissue levels of NE in the frontal cortex of saline-treated WT and DAT-KO mice (n = 7 per group).
###end p 188
###begin p 189
###xml 121 122 117 118 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 303 304 295 296 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 482 483 470 471 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 516 517 504 505 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
###xml 252 256 <span type="species:ncbi:10090">mice</span>
###xml 297 301 <span type="species:ncbi:10090">mice</span>
(D) Dynamics of the effect of alphaMT (250 mg/kg IP) on tissue levels of NE in the frontal cortex of WT and DAT-KO mice (n = 5-8 per group). NE levels were significantly lower versus control values at time points 2-16 after alphaMT treatment in DAT-KO mice and at 4-16 hours after treatment in WT mice (p < 0.05, one-way ANOVA followed by Dunnet's multiple comparison test). The magnitude of the effect was not different between genotypes at any time point after alphaMT injection (p > 0.05, two-tailed Mann-Whitney U test).
###end p 189
###begin p 190
###xml 263 264 259 260 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 279 280 271 272 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 357 358 345 346 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 391 392 379 380 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
(E) Effect of alphaMT on extracellular DA levels in the striatum of WT mice, measured using in vivo microdialysis. Data are presented as a percentage of the average level of DA measured in at least three samples collected before the drug administration. (Saline, n = 5; alphaMT, n = 7). alphaMT significantly decreased DA levels 60-180 min after treatment (p < 0.05, two-tailed Mann-Whitney U test versus respective time points in saline-treated controls).
###end p 190
###begin p 191
###xml 291 292 287 288 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 307 308 299 300 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 385 386 373 374 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 419 420 407 408 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 629 630 617 618 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 663 664 651 652 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
###xml 141 145 <span type="species:ncbi:10090">mice</span>
###xml 734 738 <span type="species:ncbi:10090">mice</span>
###xml 776 780 <span type="species:ncbi:10090">mice</span>
(F) Effect of alphaMT on extracellular levels of DA in the striatum of DAT-KO mice, measured by using in vivo microdialysis in freely moving mice. Data are presented as a percentage of the average level of DA measured in at least three samples collected before drug administration. (Saline, n = 4; alphaMT, n = 6). alphaMT significantly decreased DA levels 20-180 min after treatment (p < 0.05, two-tailed Mann-Whitney U test versus respective time points in saline-treated controls). Analysis of area under curve values for 120-min periods after drug administration revealed significant difference between DAT-KO and WT groups (p < 0.05, two-tailed Mann-Whitney U test). Note also that the basal extracellular levels of DA in DAT-KO mice were significantly higher than in WT mice (predrug concentrations of DA in dialysates were: WT, 76 +/- 17 fmol/20 mul; DAT-KO, 340 +/- 63 fmol/20 mul).
###end p 191
###begin title 192
###xml 40 44 <span type="species:ncbi:10090">Mice</span>
Display of Behavioral Phenotypes of DDD Mice
###end title 192
###begin p 193
###xml 33 37 <span type="species:ncbi:10090">mice</span>
###xml 90 94 <span type="species:ncbi:10090">mice</span>
(A) Akinesia and rigidity of DDD mice. Photos were taken 30 min after treatment of DAT-KO mice with alphaMT (250 mg/kg IP).
###end p 193
###begin p 194
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 72 76 <span type="species:ncbi:10090">mice</span>
###xml 119 124 <span type="species:ncbi:10090">Mouse</span>
###xml 167 172 <span type="species:ncbi:10090">mouse</span>
###xml 186 191 <span type="species:ncbi:10090">mouse</span>
###xml 236 241 <span type="species:ncbi:10090">mouse</span>
(B) Ptosis in DDD mice. Photos were taken 3 h after treatment of DAT-KO mice with alphaMT (250 mg/kg IP). Lower panel: Mouse on the left side is saline-treated DAT-KO mouse, whereas the mouse on the right side is alphaMT-treated DAT-KO mouse.
###end p 194
###begin title 195
###xml 54 58 <span type="species:ncbi:10090">Mice</span>
alphaMT-Induced Impairment in Motor Control in DAT-KO Mice
###end title 195
###begin p 196
###xml 192 193 188 189 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 336 337 328 329 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 356 357 348 349 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 805 826 777 798 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 970 971 942 943 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 990 991 962 963 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 997 998 969 970 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1319 1320 1287 1288 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1339 1340 1307 1308 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1347 1348 1315 1316 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 186 190 <span type="species:ncbi:10090">mice</span>
###xml 385 389 <span type="species:ncbi:10090">mice</span>
###xml 751 755 <span type="species:ncbi:10090">mice</span>
###xml 859 863 <span type="species:ncbi:10090">mice</span>
###xml 1136 1140 <span type="species:ncbi:10090">mice</span>
###xml 1514 1518 <span type="species:ncbi:10090">mice</span>
###xml 1561 1565 <span type="species:ncbi:10090">mice</span>
Dynamics of locomotor activity following systemic administration of alphaMT (250 mg/kg IP) and saline (30 min after placement in the locomotor activity chamber) in WT (A) and DAT-KO (B) mice (n = 6-8 per group). Analysis of total distance traveled for 210 min after drug administration revealed significant effect of alphaMT treatment (p < 0.05; Student's t-test) in DAT-KO but not WT mice (WT-saline, 516 +/- 50 cm/210 min; WT-alphaMT, 505 +/- 98 cm/210 min; DAT-KO-saline, 18,489 +/- 4,795 cm/210 min; DAT-KO-alphaMT, 448 +/- 75 cm/210 min). alphaMT (injected at time 0) induced profound alterations in the akinesia (C), catalepsy (D), grasping (E), bracing (F) tremor (G), and ptosis (H) tests, but did not affect the righting reflex (I) in DAT-KO mice. Behavioral tests were performed as described in Materials and Methods. At all the time points, DAT-KO mice were significantly different versus respective values (data not shown) of saline-treated DAT-KO controls (p < 0.05; Student's t-test n = 6 per group) in these tests with exception of 15-min time point for ptosis (H) and all time points for righting reflex test (I). In WT mice only the akinesia test (C) revealed minor, yet significant, effect (1.5-4 h after alphaMT treatment) versus values (data not shown) of the respective saline treated WT controls (p < 0.05; Student's t-test; n = 6 per group). No significant alterations in any other test at any time point examined (D-I) was noted in alphaMT-treated versus saline treated (data not shown) WT mice. Locomotor activity is restored in DAT-KO mice 16-24h after alphaMT (250 mg/kg IP) treatment (J).
###end p 196
###begin title 197
###xml 81 85 <span type="species:ncbi:10090">Mice</span>
L-DOPA and Nonselective DA Agonists Are Effective in Restoring Locomotion in DDD Mice
###end title 197
###begin p 198
###xml 566 567 558 559 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 600 601 592 593 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 911 912 903 904 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 945 946 937 938 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 1363 1364 1355 1356 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1397 1398 1389 1390 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 7 11 <span type="species:ncbi:10090">mice</span>
###xml 328 332 <span type="species:ncbi:10090">mice</span>
###xml 654 658 <span type="species:ncbi:10090">mice</span>
###xml 832 836 <span type="species:ncbi:10090">mice</span>
###xml 1000 1004 <span type="species:ncbi:10090">mice</span>
###xml 1291 1295 <span type="species:ncbi:10090">mice</span>
###xml 1451 1455 <span type="species:ncbi:10090">mice</span>
###xml 1509 1513 <span type="species:ncbi:10090">mice</span>
DAT-KO mice were placed in the locomotor activity chamber and 30 min later were treated with alphaMT (250 mg/kg IP) and 1 h after alphaMT were challenged with single or multiple doses of a drug (interval between treatments is 1 h). L-DOPA itself (A) or in combination with carbidopa (B-D) effectively restored locomotion in DDD mice, as revealed by the significant effect of L-DOPA at doses 100 and 200 mg/kg IP, or combinations of L-DOPA/carbidopa at doses 20/20, 50/20, and 50/50 mg/kg, IP (analysis of total distance traveled for 1 h after each dose of the drug; p < 0.05, two-tailed Mann-Whitney U test versus respective values in saline-treated DDD mice; data not shown). Nonselective DA receptor agonists, apomorphine (E) at doses 2 and 3 mg/kg SC, and pergolide (F) at doses 5, 10, and 20 mg/kg IP, induced locomotion in DDD mice (analysis of total distance traveled for 1 h after each dose of the drug; p < 0.05, two-tailed Mann-Whitney U test, versus respective values in saline-treated DDD mice; data not shown). D2 DA receptor agonists bromocriptine (G), quinpirole (H), and D1 DA receptor agonist (+)-SKF81297 (I) were not effective, but the combinations of D1 and D2 DA agonists (+)-SKF81297 plus quinpirole at doses 5/1 and 10/5 mg/kg IP, induced significant locomotion in DDD mice (analysis of total distance traveled for 1 h after each treatment; p < 0.05, two-tailed Mann-Whitney U test versus respective values in saline-treated DDD mice; data not shown). Experiments were performed in 6-12 mice per group.
###end p 198
###begin title 199
###xml 97 101 <span type="species:ncbi:10090">Mice</span>
Amphetamine Derivatives at High Doses Are Effective in Reversing Abnormal Motor Behaviors of DDD Mice
###end title 199
###begin p 200
###xml 354 375 346 367 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 537 538 527 528 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 712 713 702 703 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 729 730 719 720 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 750 751 740 741 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 7 11 <span type="species:ncbi:10090">mice</span>
###xml 593 597 <span type="species:ncbi:10090">mice</span>
###xml 696 700 <span type="species:ncbi:10090">mice</span>
DAT-KO mice were placed in the locomotor activity chamber and 30 min later were treated with alphaMT (250 mg/kg IP), and 1 h after alphaMT were challenged with single or multiple doses of drugs (in cumulative dosing experiments, the interval between treatments was 1 h). Grasping (A), catalepsy (B), and akinesia (C) tests were performed as described in Materials and Methods 1 h after each dose (the only exception is (+/-)-MDMA at 80 mg/kg IP where measurements were performed 2 h after the drug administration). An asterisk indicates p < 0.05 versus respective values of saline-treated DDD mice (one-way ANOVA followed by Dunnet's multiple comparison test). Experiments were performed in 6-16 mice per group. d-AMPH indicates d-amphetamine; METH, d-methamphetamine; and 4-chloro-AMPH, 4-chloro-amphetamine.
###end p 200
###begin title 201
###xml 43 47 <span type="species:ncbi:10090">Mice</span>
(+)-MDMA Induces Forward Locomotion in DDD Mice
###end title 201
###begin p 202
###xml 252 253 244 245 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 571 572 563 564 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 362 366 <span type="species:ncbi:10090">mice</span>
###xml 670 674 <span type="species:ncbi:10090">mice</span>
(A-C) DAT-KO mice were placed in the locomotor activity chamber and 30 min later were treated with alphaMT (250 mg/kg IP) and 1 h after alphaMT were challenged with single (B and C) or multiple doses (A) of a drug (interval between treatments is 1 h) (n = 10-16 per group). Repeated treatment with (+)-MDMA (30 and 60 mg/kg IP) induces forward locomotion in DDD mice (A). Analysis of total distance traveled for 1 h after 60 mg/kg IP of (+)-MDMA reveals significant effect of treatment versus respective period in saline-treated controls (p<0.05, two-tailed Mann-Whitney U test, data not shown). Dynamics (B) and dose-response (C) of locomotor effect of (+)-MDMA in DDD mice are shown. Pretreatment with D1 and D2 DA antagonists (SCH23390, 0.1 mg/kg SC plus raclopride, 2 mg/kg IP) 30 min before 100 mg/kg IP (+)-MDMA) did not affect locomotor action of (+)-MDMA (C).
###end p 202
###begin p 203
###xml 260 261 256 257 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 444 452 440 448 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="pbio-0030271-g001">Figure 1</xref>
###xml 455 456 451 452 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 489 490 485 486 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
(D) (+)-MDMA (100 mg/kg IP) fails to affect DA dynamics in the striatum of DDD mice as measured by in vivo microdialysis. Data are presented as a percentage of the average level of DA measured in at least three samples collected before alphaMT administration (n = 4). Analysis of area under curve values for 120-min periods after (+)-MDMA administration revealed no significant difference in comparison with respective values in control group (Figure 1F; p > 0.05, two-tailed Mann-Whitney U test).
###end p 203
###begin p 204
###xml 34 35 34 35 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 52 53 52 53 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 412 413 404 405 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 510 511 502 503 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 528 529 520 521 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 663 664 655 656 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 198 202 <span type="species:ncbi:10090">mice</span>
(E and F) (+)-MDMA (E) as well as d-amphetamine and d-methamphetamine (F) at moderate doses potentiate locomotor-stimulating effect of subthreshold dose of L-DOPA/carbidopa (10/10 mg/kg IP). DAT-KO mice were treated with alphaMT as described above (A-C) and 45 min after alphaMT were injected with amphetamines. L-DOPA/carbidopa was injected 15 min after amphetamines, and distance traveled for 2h was measured (n = 6-15 per group). Note, that no forward locomotion was observed after these doses of (+)-MDMA, d-amphetamine and d-methamphetamine without L-DOPA/carbidopa, whereas L-DOPA/carbidopa (presented as drug dose 0) induced only a modest but significant (p < 0.05) increase in locomotion over saline-treated controls (data not shown).
###end p 204
###begin p 205
###xml 26 27 26 27 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 62 63 62 63 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 102 103 102 103 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 233 234 233 234 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 242 243 242 243 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 250 251 250 251 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
###xml 271 272 271 272 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">d</italic>
Single asterisk indicates p < 0.05; double asterisks indicate p < 0.01; and triple asterisks indicate p < 0.001 versus saline-treated controls (C) or L-DOPA/carbidopa-treated (10/10 mg/kg IP) group (E and F) (two-tailed Mann-Whitney U test). d-AMPH, d-amphetamine; METH, d-methamphetamine.
###end p 205
###begin title 206
###xml 89 93 <span type="species:ncbi:10090">Mice</span>
Nomifensine, but Not GBR12909, Is Effective in Reversing Abnormal Motor Behaviors of DDD Mice
###end title 206
###begin p 207
###xml 247 248 243 244 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 335 356 331 352 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 406 407 402 403 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 442 443 438 439 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 482 483 478 479 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 818 819 814 815 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 7 11 <span type="species:ncbi:10090">mice</span>
###xml 117 121 <span type="species:ncbi:10090">Mice</span>
###xml 539 543 <span type="species:ncbi:10090">mice</span>
###xml 669 673 <span type="species:ncbi:10090">mice</span>
###xml 756 760 <span type="species:ncbi:10090">mice</span>
###xml 812 816 <span type="species:ncbi:10090">mice</span>
DAT-KO mice were placed in the locomotor activity chamber and 30 min later were treated with alphaMT (250 mg/kg IP). Mice were challenged 1 h later with two doses (10 and 30 mg/kg IP) of each drug or saline with a 1 h interval between treatments (n = 9-15 per group). Grasping (A) and akinesia (B) tests were performed as described in Materials and Methods 1 h after each dose. A single asterisk indicates p < 0.05, double asterisks indicate p < 0.01, and triple asterisks indicate p < 0.001 versus respective values of saline-treated DDD mice (one-way ANOVA followed by Dunnet's multiple comparison test). Note that no significant differences between GBR12909-treated mice and saline-treated controls in both tests were found, whereas nomifensine-treated mice were significantly different from GBR12909-treated mice (p < 0.05) in both experimental paradigms and doses tested.
###end p 207
###begin title 208
###xml 74 78 <span type="species:ncbi:10090">Mice</span>
Treatments That Were Not Effective in Restoring Forward Locomotion in DDD Mice
###end title 208

